Why Atossa Therapeutics, Inc.’s (ATOS) Stock Is Down 5.97%
As of Tuesday, May 05, Atossa Therapeutics, Inc.’s ATOS share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Cynthia McLaughlin
Cynthia McLaughlin
Jenna Brashear
Tudor Pop
| Share Statistics | ATOS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.9 | $203.5 | 10% |
|
| Shares Out (Mil) | 10.0 | 55.2 | 21% |
|
| Institutional Ownership | 96.2% | 93.3% | 69% |
|
| Float (Mil) | 9.9 | 40.4 | 19% |
|
| Beta | 1.37 | 1.05 | 77% |
|
| Avg Daily Volume (000s) | 52 | 569 | 29% |
|
| Price Change (52-week) |
(86.1%) | 38.8% | 7% |
|
| Growth | ATOS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (14.3%) | (10.7%) | 26% |
|
| EPS (5yr) | 32.9% | 15.4% | 84 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.0%) | (15.7%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.780) | ($3.560) | ($3.300) | |
| Month Ago EPS | ($0.780) | ($3.560) | ($3.300) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($1.100) | ($4.400) | ($4.380) | |
| Year/Year Chg | 38.3% | (11.8%) | (161.7%) | |
| Financials | ATOS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($35) | ($44) | 19% |
|
| EPS (TTM) | ($3.838) | ($1.400) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($35) | ($35) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $142 | 4% |
|
| Valuation | ATOS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.73 | 1.96 | 20% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ATOS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (82.1%) | (47.0%) | 6% |
|
| ROE | (96.9%) | (51.8%) | 9% |
|
| Liabilities to Assets | 17.8% | 29.6% | 11% |
|
| F-Score | 0 | 3 | 0% |
|
Atossa Therapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors